{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:36:51Z","timestamp":1761514611260},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It is of utmost importance to investigate novel therapies for cancer, as it is a major cause of death. In recent years, immunotherapies, especially those against immune checkpoints, have been developed and brought significant improvement in cancer management. However, on the other hand, immune checkpoints blockade (ICB) by monoclonal antiboties may cause common and severe adverse reactions (ADRs), the cause of which remains largely undetermined. We hypothesize that ICB-agents may induce adverse reactions through off-target protein interactions, similar to the ADR-causing off-target effects of small molecules. In this study, we propose a hybrid phenotype mining approach which integrates molecular level information and provides new mechanistic insights for ICB-associated ADRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We trained a conditional random fields model on the TAC 2017 benchmark training data, then used it to extract all drug-centric phenotypes for the five anti-PD-1\/PD-L1 drugs from the drug labels of the DailyMed database. Proteins with structure similar to the drugs were obtained by using BlastP, and the gene targets of drugs were obtained from the STRING database. The target-centric phenotypes were extracted from the human phenotype ontology database. Finally, a screening module was designed to investigate off-target proteins, by making use of gene ontology analysis and pathway analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eventually, through the cross-analysis of the drug and target gene phenotypes, the off-target effect caused by the mutation of gene BTK was found, and the candidate side-effect off-target site was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This research provided a hybrid method of biomedical natural language processing and bioinformatics to investigate the off-target-based mechanism of ICB treatment. The method can also be applied for the investigation of ADRs related to other large molecule drugs.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12911-020-1105-4","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T08:08:50Z","timestamp":1594282130000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Yuyu","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Zweigenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"1105_CR1","doi-asserted-by":"crossref","unstructured":"Couzin-Frankel J. Cancer immunotherapy. Am Assoc Adv Sci. 2013.","DOI":"10.1126\/science.342.6165.1432"},{"issue":"4","key":"1105_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1105_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","volume":"4","author":"J Dine","year":"2017","unstructured":"Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia-Pacific J Oncol Nurs. 2017; 4(2):127.","journal-title":"Asia-Pacific J Oncol Nurs"},{"issue":"3","key":"1105_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8(3):239.","journal-title":"Nat Immunol"},{"issue":"6","key":"1105_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","volume":"141","author":"J Guan","year":"2017","unstructured":"Guan J, Lim KS, Mekhail T, Chang C-C. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)\/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med. 2017; 141(6):851\u201361.","journal-title":"Arch Pathol Lab Med"},{"key":"1105_CR6","doi-asserted-by":"crossref","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, et al.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Inv. 2018; 128(2).","DOI":"10.1172\/JCI96061"},{"issue":"3","key":"1105_CR7","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","volume":"64","author":"C Blank","year":"2004","unstructured":"Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64(3):1140\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"1105_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.blre.2014.09.004","volume":"29","author":"LJ Bryan","year":"2015","unstructured":"Bryan LJ, Gordon LI. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev. 2015; 29(1):25\u201332.","journal-title":"Blood Rev"},{"issue":"2","key":"1105_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, et al.Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017; 5(2):106\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1105_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017; 214(4):895\u2013904.","journal-title":"J Exp Med"},{"key":"1105_CR11","doi-asserted-by":"crossref","unstructured":"Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. In: Seminars in Oncology. volume 44. Elsevier: 2017. p. 136\u201340.","DOI":"10.1053\/j.seminoncol.2017.06.002"},{"issue":"suppl_1","key":"1105_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006; 34(suppl_1):668\u201372.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1105_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2017","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, et al.DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017; 46(D1):1074\u201382.","journal-title":"Nucleic Acids Res"},{"key":"1105_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, B\u00e4hr O, Eigentler TK, Grimm M-O, Gr\u00fcnwald V, Leipe J, Reinmuth N, Tietze JK, et al.Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017; 57:36\u201349.","journal-title":"Cancer Treat Rev"},{"key":"1105_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Gr\u00fcnwald V, K\u00e4hler KC, Loquai C, Reinmuth N, Steins M, et al.Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Rev. 2016; 45:7\u201318.","journal-title":"Cancer Treatment Rev"},{"issue":"5886","key":"1105_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.1158140","volume":"321","author":"M Campillos","year":"2008","unstructured":"Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008; 321(5886):263\u20136.","journal-title":"Science"},{"issue":"7270","key":"1105_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","volume":"462","author":"MJ Keiser","year":"2009","unstructured":"Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et al.Predicting new molecular targets for known drugs. Nature. 2009; 462(7270):175.","journal-title":"Nature"},{"issue":"3","key":"1105_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1504\/IJDMB.2018.097684","volume":"21","author":"AC Fang","year":"2018","unstructured":"Fang AC, Liu Y, Lu Y, Cao J, Xia J. A corpus-oriented perspective on terminologies of side effect and adverse reaction in support of text retrieval for drug repurposing. Int J Data Min Bioinforma. 2018; 21(3):269\u201386.","journal-title":"Int J Data Min Bioinforma"},{"key":"1105_CR19","doi-asserted-by":"crossref","unstructured":"Zhou K, Zhang S, Meng X, Luo Q, Wang Y, Ding K, Feng Y, Chen M, Cohen K, Xia J. CRF-LSTM text mining method unveiling the pharmacological mechanism of off-target side effect of anti-multiple myeloma drugs. In: Proceedings of the BioNLP 2018 Workshop: 2018. p. 166\u201371.","DOI":"10.18653\/v1\/W18-2321"},{"key":"1105_CR20","unstructured":"Zhou K, Zhang X, Zweigenbaum P, Liang R, Jiang Y, Xia J. Adverse reaction identification driven by semantic information. In: TAC: 2017."},{"key":"1105_CR21","doi-asserted-by":"crossref","unstructured":"Wei C-H, Allot A, Leaman R, Lu Z. Pubtator central: automated concept annotation for biomedical full text articles. Nucleic Acids Res. 2019; 47(W1).","DOI":"10.1093\/nar\/gkz389"},{"key":"1105_CR22","doi-asserted-by":"crossref","unstructured":"Gachloo M, Wang Y, Xia J. A review of drug knowledge discovery using bionlp and tensor or matrix decomposition. Genomics Inf. 2019; 17(2).","DOI":"10.5808\/GI.2019.17.2.e18"},{"key":"1105_CR23","unstructured":"Cohen KB, Xia J, Roeder C, Hunter LE. Reproducibility in natural language processing: a case study of two r libraries for mining pubmed\/medline. In: LREC... International Conference on Language Resources & Evaluation:[proceedings]. International Conference on Language Resources and Evaluation. volume 2016. NIH Public Access: 2016. p. 6."},{"key":"1105_CR24","doi-asserted-by":"crossref","unstructured":"Wei Q, Chen T, Xu R, He Y, Gui L. Disease named entity recognition by combining conditional random fields and bidirectional recurrent neural networks. Database. 2016; 2016.","DOI":"10.1093\/database\/baw140"},{"issue":"1","key":"1105_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/cr.2016.102","volume":"27","author":"K Liu","year":"2017","unstructured":"Liu K, Tan S, Chai Y, Chen D, Song H, Zhang WH, Shi Y, Liu J, Tan W, Lyu J. Structural basis of anti-PD-l1 monoclonal antibody avelumab for tumor therapy. Cell Res. 2017; 27(1):151.","journal-title":"Cell Res"},{"issue":"1","key":"1105_CR26","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","volume":"7","author":"HT Lee","year":"2017","unstructured":"Lee HT, Ju YL, Lim H, Sang HL, Yu JM, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1\/PD-l1 blockade via anti-PD-l1 antibodies atezolizumab and durvalumab. Sci Rep. 2017; 7(1):5532.","journal-title":"Sci Rep"},{"key":"1105_CR27","doi-asserted-by":"publisher","first-page":"14369","DOI":"10.1038\/ncomms14369","volume":"8","author":"S Tan","year":"2017","unstructured":"Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ. An unexpected n-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017; 8:14369.","journal-title":"Nat Commun"},{"key":"1105_CR28","doi-asserted-by":"crossref","unstructured":"Roberts K, Demner-Fushman D, Tonning JM. Overview of the TAC 2017 adverse reaction extraction from drug labels track. In: TAC: 2017.","DOI":"10.6028\/NIST.SP.500-324.pm-overview"},{"issue":"3","key":"1105_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/JCP.0b013e318218f3e4","volume":"31","author":"J de Leon","year":"2011","unstructured":"de Leon J. Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol. 2011; 31(3):263\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"Database issue","key":"1105_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/nar\/gkw1039","volume":"45","author":"S K\u00f6hler","year":"2017","unstructured":"K\u00f6hler S, Vasilevsky NA, Engelstad M, Foster E, Mcmurry J, Aym\u00e9 S, Baynam G, Bello SM, Boerkoel CF, Boycott KM. The Human Phenotype Ontology in 2017. Nucleic Acids Res. 2017; 45(Database issue):865\u201376.","journal-title":"Nucleic Acids Res"},{"key":"1105_CR31","unstructured":"Korf I, Yandell M, Bedell J. Blast: O\u2019Reilly Media, Inc.; 2003."},{"key":"1105_CR32","doi-asserted-by":"crossref","unstructured":"Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A. Uniprotkb\/swiss-prot. In: Plant Bioinformatics. Springer: 2007. p. 89\u2013112.","DOI":"10.1007\/978-1-59745-535-0_4"},{"key":"1105_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015; 35:76\u201383.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1105_CR34","volume-title":"Proceedings of the 48th Annual Meeting of the Association for Computational Linguistics","author":"T Lavergne","year":"2010","unstructured":"Lavergne T, Capp\u00e9 O, Yvon F. Practical very large scale CRFs. In: Proceedings of the 48th Annual Meeting of the Association for Computational Linguistics. Uppsala: Association for Computational Linguistics: 2010. p. 504\u2013513."},{"issue":"Pt 1","key":"1105_CR35","first-page":"216","volume":"84","author":"AT McCray","year":"2001","unstructured":"McCray AT, Burgun A, Bodenreider O. Aggregating UMLS semantic types for reducing conceptual complexity. Stud Health Technol Inform. 2001; 84(Pt 1):216\u201320.","journal-title":"Stud Health Technol Inform"},{"issue":"Database issue","key":"1105_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/nar\/gkh061","volume":"32","author":"O Bodenreider","year":"2004","unstructured":"Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004; 32(Database issue):267\u201370.","journal-title":"Nucleic Acids Res"},{"key":"1105_CR37","doi-asserted-by":"crossref","unstructured":"Mattsson PT, Vihinen M, Smith CI. Bioessays News Rev Mol Cell Dev Biol. 2010; 18(10):825\u201334.","DOI":"10.1002\/bies.950181009"},{"issue":"2","key":"1105_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2340\/00015555-2501","volume":"97","author":"M Sugimoto","year":"2016","unstructured":"Sugimoto M, Takeichi T, Muramatsu H, Kojima D, Osada Y, Kono M, Kojima S, Akiyama M. Recurrent cellulitis caused by helicobacter cinaedi in a patient with X-linked agammaglobulinaemia. Acta Dermato-Venereologica. 2016; 97(2):277\u20138.","journal-title":"Acta Dermato-Venereologica"},{"key":"1105_CR39","doi-asserted-by":"crossref","unstructured":"Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, \u00d6llinger R, Maresch R, Buch T, Steiger K, Winter C. Erratum: PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017; 553(7683).","DOI":"10.1038\/nature25142"},{"issue":"416","key":"1105_CR40","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1126\/scitranslmed.aam7543","volume":"9","author":"NM Ben","year":"2017","unstructured":"Ben NM, Tezza S, D\u2019Addio F, Mameli C, Usuelli V, Maestroni A, Corradi D, Belletti S, Albarello L, Becchi G. PD-l1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Trans Med. 2017; 9(416):7543.","journal-title":"Sci Trans Med"},{"key":"1105_CR41","doi-asserted-by":"crossref","unstructured":"Ludin A, Zon LI. Cancer immunotherapy: The dark side of PD-1 receptor inhibition. Nature. 2017; 552(7683).","DOI":"10.1038\/nature24759"},{"issue":"1","key":"1105_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"NV Sasidharan","year":"2018","unstructured":"Sasidharan NV, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018; 96(1):21.","journal-title":"Immunol Cell Biol"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-1105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-020-1105-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-1105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:09:23Z","timestamp":1723219763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-020-1105-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":42,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1186\/s12911-020-1105-4","relation":{},"ISSN":["1472-6947"],"issn-type":[{"type":"electronic","value":"1472-6947"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"9 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors read and approved the final manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}